DCC 'Sv. Pantaleymon' OOD
Welcome,         Profile    Billing    Logout  
 9 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bouguen, Guillaume
ACTIVE, NCT02425852: A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis

Completed
4
65
Europe
Azathioprine, Infliximab, Prednisolone, Hydrocortisone
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Ulcerative Colitis
06/22
01/23
USTAP, NCT04496063: USTekinumab in Fistulising Perianal Crohn's Disease

Active, not recruiting
4
33
Europe
Ustekinumab, Stelara, Placebo
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Janssen, LP
Crohn's Disease
06/25
12/25
EFFICACI, NCT03679546 / 2018-002673-21: : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis

Active, not recruiting
4
150
Europe
Infliximab, Infliximab injection, Vedolizumab Injection, Vedolizumab
Rennes University Hospital
Ulcerative Colitis
12/24
05/25
VEDIAN, NCT06180382: Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

Recruiting
4
220
Europe
Adalimumab, Vedolizumab
Centre Hospitalier Universitaire de Saint Etienne, Takeda France
Crohn's Disease
01/26
01/27
NCT04183608 / 2018-003490-10: A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab

Recruiting
4
238
Europe
Adalimumab, Calprotectin, e-Monitoring, Therapy Education
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, AbbVie
Ulcerative Colitis
04/25
05/28
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
SAPHIR, NCT05598684: : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases

Recruiting
N/A
600
Europe, RoW
Fresenius Kabi, France
Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
09/25
12/25
CROHN-PREP, NCT05117996: Simplified Bowel Preparation Versus Standard Bowel Preparation Before Capsule Endoscopy in Patients With Crohn's Disease

Completed
N/A
144
Europe
capsule endoscopy, standard small bowel preparation, Simplified small bowel preparation
Nantes University Hospital
Crohn Disease
03/24
04/24
BIOÏDES, NCT05294107: Intestinal Organoids

Recruiting
N/A
90
Europe
additional biopsies
Rennes University Hospital
Digestive System Diseases, Inflammatory Bowel Disease, Ulcerative Colitis Type, Crohn Disease
03/26
03/26
SPACIFIX, NCT03841942: Comparison of Trough Level- and Clinical-based Spacing of Infliximab Infusions in Patients With IBD in Deep Remission

Terminated
N/A
64
Europe
clinically-based spacing strategy, Trough level-based strategy
University Hospital, Montpellier
Inflammatory Bowel Diseases
10/23
10/23
TRENCH 1, NCT05903066: TRansmural hEaliNg Definition in CroHn's Disease

Recruiting
N/A
210
Europe
Magnetic Resonance Enterography (MRE)
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Crohn Disease
07/25
08/25
Deeper, NCT04973423: STUDY OF THE ADDED VALUE OF A TRANSMURAL EVALUATION IN PATIENTS WITH CROHN'S DISEASE UNDER BIOTHERAPY WITH CLOSE FECAL CALPROTECTIN FOLLOW-UP

Recruiting
N/A
180
Europe
MRI
University Hospital, Clermont-Ferrand
Crohn Disease, Calprotectin, MRI
03/27
08/27
Petkov, Plamen
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
06/24
06/24
ENSURE-1, NCT05134441 / 2021-000028-36: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Recruiting
3
1050
Europe, US, RoW
IMU-838 tablets, vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium
Immunic AG, Immunic AG
Multiple Sclerosis
09/24
09/32
Tankova, Ludmila
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bouguen, Guillaume
ACTIVE, NCT02425852: A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis

Completed
4
65
Europe
Azathioprine, Infliximab, Prednisolone, Hydrocortisone
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Ulcerative Colitis
06/22
01/23
USTAP, NCT04496063: USTekinumab in Fistulising Perianal Crohn's Disease

Active, not recruiting
4
33
Europe
Ustekinumab, Stelara, Placebo
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Janssen, LP
Crohn's Disease
06/25
12/25
EFFICACI, NCT03679546 / 2018-002673-21: : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis

Active, not recruiting
4
150
Europe
Infliximab, Infliximab injection, Vedolizumab Injection, Vedolizumab
Rennes University Hospital
Ulcerative Colitis
12/24
05/25
VEDIAN, NCT06180382: Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

Recruiting
4
220
Europe
Adalimumab, Vedolizumab
Centre Hospitalier Universitaire de Saint Etienne, Takeda France
Crohn's Disease
01/26
01/27
NCT04183608 / 2018-003490-10: A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab

Recruiting
4
238
Europe
Adalimumab, Calprotectin, e-Monitoring, Therapy Education
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, AbbVie
Ulcerative Colitis
04/25
05/28
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
SAPHIR, NCT05598684: : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases

Recruiting
N/A
600
Europe, RoW
Fresenius Kabi, France
Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
09/25
12/25
CROHN-PREP, NCT05117996: Simplified Bowel Preparation Versus Standard Bowel Preparation Before Capsule Endoscopy in Patients With Crohn's Disease

Completed
N/A
144
Europe
capsule endoscopy, standard small bowel preparation, Simplified small bowel preparation
Nantes University Hospital
Crohn Disease
03/24
04/24
BIOÏDES, NCT05294107: Intestinal Organoids

Recruiting
N/A
90
Europe
additional biopsies
Rennes University Hospital
Digestive System Diseases, Inflammatory Bowel Disease, Ulcerative Colitis Type, Crohn Disease
03/26
03/26
SPACIFIX, NCT03841942: Comparison of Trough Level- and Clinical-based Spacing of Infliximab Infusions in Patients With IBD in Deep Remission

Terminated
N/A
64
Europe
clinically-based spacing strategy, Trough level-based strategy
University Hospital, Montpellier
Inflammatory Bowel Diseases
10/23
10/23
TRENCH 1, NCT05903066: TRansmural hEaliNg Definition in CroHn's Disease

Recruiting
N/A
210
Europe
Magnetic Resonance Enterography (MRE)
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Crohn Disease
07/25
08/25
Deeper, NCT04973423: STUDY OF THE ADDED VALUE OF A TRANSMURAL EVALUATION IN PATIENTS WITH CROHN'S DISEASE UNDER BIOTHERAPY WITH CLOSE FECAL CALPROTECTIN FOLLOW-UP

Recruiting
N/A
180
Europe
MRI
University Hospital, Clermont-Ferrand
Crohn Disease, Calprotectin, MRI
03/27
08/27
Petkov, Plamen
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
06/24
06/24
ENSURE-1, NCT05134441 / 2021-000028-36: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Recruiting
3
1050
Europe, US, RoW
IMU-838 tablets, vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium
Immunic AG, Immunic AG
Multiple Sclerosis
09/24
09/32
Tankova, Ludmila
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30

Download Options